A Facebook share points to a piece on how losing weight with drugs like Ozempic may affect bone health, as use for diabetes and weight loss grows.
Recap by typeshit. Post by Facebook on Facebook.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Egyptian researchers followed 48 adults with type 1 diabetes and obesity who were using tirzepatide on their own, and presented the work at a meeting in Milan.
An Arabic-language Instagram clip from Dr Israa Sous on stepping up to the higher 7.2 mg Wegovy injection dose. Her take on timing, not a fixed rule.
Loading…